Kaspar van den Dries, Ph.D.

Science & Innovation Sr. Director, Softgels, Pharma Services
Tilburg, Netherlands

Key roles and responsibilities

  • Head of research and development for the softgels business unit at Thermo Fisher Scientific, leading the development teams at the High Point, NC and Tilburg sites
  • Help clients choose and develop the right dosage forms and technologies to meet their goals from development through commercial manufacturing
  • Provide leadership to technical teams at early development site in Milton Park, U.K. and late stage development site in Bourgoin, France

Professional highlights

  • Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
  • Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida, and assistant professor of pediatrics at Harvard Medical School
  • Experience in viral vector industry spans over thirty-three years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
  • Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
  • Author of over seventy scientific publications and also eight U.S. patents


  • Doctor of Philosophy and Master’s degree in pharmaceutical sciences from the University of Utrecht, NL

Scientific expertise

  • Formulation & process development
    • Solid dose formulation (tablets, capsules, and softgels)
    • Late stage process development projects
    • Technology transfer
    • Regulatory filings
  • Solubility enhancement
    • Biopharmaceuticals
    • Lipid-based formulations
  • Quality by design
    • Risk assessment and experimental designs
    • Process analytical technologies (NIR)
    • In vitro – in vivo relationships

Related Sites

Additional Resources